Current Trends in the Treatment of Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer -

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Journal of pharmacy and nutrition sciences

• Publication date

  2020-01-05

• Fields of study

  Medicine

• Identifiers
  DOI 10.29169/1927-5951.2020.10.01.8
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Updates in the Evaluation and Management of Breast Cancer

  2018cited by this paper
• Progress in targeted therapy for breast cancer

  2018cited by this paper
• Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells

  2018cited by this paper
• Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

  2018cited by this paper
• Estrogen promotes estrogen receptor negative BRCA1-deficient tumor initiation and progression

  2018cited by this paper
• Clinical and molecular aspects of breast cancer: Targets and therapies.

  2018cited by this paper
• Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.

  2018cited by this paper
• Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3.

  2018cited by this paper
• Chemotherapeutic agents for the treatment of metastatic breast cancer: An update.

  2018cited by this paper
• Breast Cancer : A Guide to Clinical Practice

  2018cited by this paper
• Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

  2018cited by this paper
• Correction: Association of symptoms and interval breast cancers in the mammography-screening programme: population-based matched cohort study

  2018cited by this paper
• A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO)

  2018cited by this paper
• Recent developments in topoisomerase-targeted cancer chemotherapy

  2018cited by this paper
• Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells.

  2017cited by this paper
• Hormone Therapy in Breast Cancer.

  2017cited by this paper
• Platinum containing regimens for metastatic breast cancer.

  2017cited by this paper
• Over surgery in breast cancer.

  2017cited by this paper
• Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors

  2017cited by this paper
• Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

  2017cited by this paper
• Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

  2017cited by this paper
• Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.

  2016cited by this paper
• PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting

  2016cited by this paper
• Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies

  2015cited by this paper
• Cognitive Behavior Therapy for Patients With Cancer

  2015cited by this paper
• An update on the medical management of breast cancer

  2014cited by this paper
• Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy.

  2014cited by this paper
• Nutrition and physical activity influence on breast cancer incidence and outcome.

  2013cited by this paper
• The principles of cancer treatment by chemotherapy

  2012cited by this paper
• Drugs that target dynamic microtubules: A new molecular perspective

  2011cited by this paper
• Recognising symptoms of breast cancer as a reason for delayed presentation in Asian women--the psycho-socio-cultural model for breast symptom appraisal: opportunities for intervention.

  2011cited by this paper
• Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk.

  2011cited by this paper
• VARIOUS TYPES AND MANAGEMENT OF BREAST CANCER: AN OVERVIEW

  2010cited by this paper
• Carcinogenic Alkylating Agents

  2010cited by this paper
• Sex Hormone Levels, Breast Cancer Risk, and Cancer Receptor Status in Postmenopausal Women: the ORDET Cohort

  2009cited by this paper
• Neoplastic disease and immunosuppression

  2008cited by this paper
• Managing Cancer Pain With Nonpharmacologic and Complementary Therapies

  2007cited by this paper
• Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers

  2007cited by this paper
• The role of estrogen in the initiation of breast cancer.

  2006cited by this paper
• Breast cancer in Belarus and Ukraine after the Chernobyl accident

  2006cited by this paper
• Estrogen carcinogenesis in breast cancer.

  2006cited by this paper
• Chronic Conditions, Functional Limitations, and Special Health Care Needs of School-Aged Children Born With Extremely Low-Birth-Weight in the 1990s

  2005cited by this paper
• Body size and breast cancer risk: Findings from the European prospective investigation into cancer and nutrition (EPIC)

  2004cited by this paper
• Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2

  2003cited by this paper
• Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.

  2003cited by this paper
• Implementation of the Women's Health Initiative study design.

  2003cited by this paper
• Roles of the PI-3K and MEK pathways in Ras-mediated chemoresistance in breast cancer cells

  2003cited by this paper
• Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.

  2000cited by this paper
• Estrogen receptor-mediated processes in normal and cancer cells.

  2000cited by this paper
• Breast cancer : molecular genetics, pathogenesis, and therapeutics

  1999cited by this paper
• Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.

  1998cited by this paper
• Reproductive risk factors in a prospective study of breast cancer: the Nurses' Health Study.

  1994cited by this paper
• Age at menarche, age at menopause, height and obesity as risk factors for breast cancer: Associations and interactions in an international case‐control study

  1990cited by this paper

• No citing papers are available for this paper.